structuring question

Case structure and frameworks issue tree pharma revenue
Neue Antwort am 25. Juni 2023
3 Antworten
793 Views
Anonym A fragte am 17. Juni 2021

Hi everyone,

I came across this question in a case book and was wondering what sort of opening structure would be best here, since the revenue changes by product segment are only presented to the candidate after the initial structure is presented. How would you go beyond revenues = qty x price for this question?

our client is a multinational pharmaceutical and biologics company. The client has a portfolio of drugs for major disease areas, including cancer, cardiovascular, and gastrointestinal diseases, to name a few. The client has experienced a decline in revenue over the last 18 months, and is fearful of further declines, especially given that its most commercially successful drug, which treats acid reflux disease, will be going off of patent in May of next year. What are the areas they should look into to change the course of this trend?

(editiert)

Übersicht der Antworten

Upvotes
  • Upvotes
  • Datum aufsteigend
  • Datum absteigend
Beste Antwort
Ian
Experte
Content Creator
antwortete am 17. Juni 2021
#1 BCG coach | MBB | Tier 2 | Digital, Tech, Platinion | 100% personal success rate (8/8) | 95% candidate success rate

Hi there,

Really important to have a strong structure here:

Improve Existing Business/Products

  • Identify which major products are declining in revenues
    • Figure out why
      • Price changes by us
      • Price changes by competitors
      • Volume changes - product comparison
    • Resolve
      • Adjust prices
      • Invest in mitigating measures (further R&A, better marketing/branding, etc)
  • Identify which major products are not declining in revenues
    • Figure out how to increase revenues further (i.e. milk your cash cow more)
      • Adjust prices
      • Invest in revenue-generating measures (further R&A, better marketing/branding, etc)

Build out new revenue streams - accelerate existing pipeline

  • Increase FDA approval timeline (leverage covid-acceleration knowledge here)
  • Increase FDA approval odds/chances
  • Increase time-to-market upon approval
    • Setup production early
    • Begin marketing early/fast
    • Establish distribution channels

Build out new revenue streams - begin R&D on new drugs

  • Those with:
    • Big growing markets
    • Lack of existing drugs/remedies
    • Similar to what we currently produce (i.e our expertise)
    • Good margins

Build out new revenue streams - buy

  • Other companies
  • Other patents
War diese Antwort hilfreich?
Henning
Experte
antwortete am 27. Juni 2021
Bain | passed >15 MBB interviews as a candidate

Few thoughts:

First of all you'll need to break out quantity and price into the different drugs and categories like desease and patent protection.

Once you know where the problem stems from (e.g. a specific desease), you can understand the root causes by going a level deeper. E.g. does the decline come from a decline of a specific desease - then you can look at number of patients in the market and market share, is it broadly distributed over the all products - then you can dig into marketing spend per dose, etc...

War diese Antwort hilfreich?
Vernan antwortete am 25. Juni 2023

I'm impressed by the wealth of information available on methods and supplements for preventing dca supplement side effects on this website. When considering any treatment, it's crucial to be aware of potential side effects and how to mitigate them effectively. This article provides practical insights into strategies, supplements, and lifestyle modifications that can minimize DCA's adverse effects. By implementing these preventive measures, individuals can feel more confident and supported in their decision to explore DCA as a cancer treatment option. The comprehensive nature of the information makes it a valuable resource for anyone considering or currently using DCA therapy

War diese Antwort hilfreich?
10

Ian

Content Creator
#1 BCG coach | MBB | Tier 2 | Digital, Tech, Platinion | 100% personal success rate (8/8) | 95% candidate success rate
1.088
Meetings
76.122
Q&A Upvotes
227
Awards
5,0
150 Bewertungen
Wie wahrscheinlich ist es, dass du uns einem Freund oder Kommilitonen empfiehlst?
0
1
2
3
4
5
6
7
8
9
10
0 = Nicht wahrscheinlich
10 = Sehr wahrscheinlich